BDTX vs. VALN, ARVN, MAZE, OPT, RGNX, CGEM, TYRA, AUTL, ETON, and ATAI
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Valneva (VALN), Arvinas (ARVN), Maze Therapeutics (MAZE), Opthea (OPT), REGENXBIO (RGNX), Cullinan Therapeutics (CGEM), Tyra Biosciences (TYRA), Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs.
Valneva (NASDAQ:VALN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
Black Diamond Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -4.35%. Valneva's return on equity of -3.93% beat Black Diamond Therapeutics' return on equity.
Valneva presently has a consensus price target of $15.50, indicating a potential upside of 149.60%. Black Diamond Therapeutics has a consensus price target of $14.60, indicating a potential upside of 502.06%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Valneva.
In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Black Diamond Therapeutics and 6 mentions for Valneva. Black Diamond Therapeutics' average media sentiment score of 1.53 beat Valneva's score of 0.30 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Black Diamond Therapeutics received 14 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 70.89% of users gave Black Diamond Therapeutics an outperform vote while only 66.67% of users gave Valneva an outperform vote.
Valneva has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500.
Black Diamond Therapeutics has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
11.4% of Valneva shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Black Diamond Therapeutics beats Valneva on 12 of the 17 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 6/11/2025 by MarketBeat.com Staff
